This CME program will provide an update on the assessment and therapeutic management of cognitive decline in patients with multiple sclerosis (MS). The expert faculty, Dr. Ann Bass, will first cover multiple sclerosis cognition dysfunction in the modern treatment era, highlighting various measurement tools. Following, recent clinical trial data regarding treatment and prevention of cognitive decline will be reviewed, including a discussion of modifiable risk factors for gray matter atrophy. Dr. Bass will conclude with implications for clinical practice, utilizing a case-based approach. Upon completion of this CME activity, learners will be able to better assess and manage cognitive decline in their multiple sclerosis patients.
Neurologists and other healthcare professionals involved in the treatment and management of patients with multiple sclerosis
I. Update on the Science and Assessment of Cognition in Patients with MS
II. Strategies to Delay Cognitive Decline in Patients with Multiple Sclerosis, Including the Role of S1P-Based Therapeutics
- Review the science and assessment of cognition in patients with multiple sclerosis
- Analyze recent data and clinical applications of therapeutics that manage cognition, including S1P-based therapies
Disclosures of Relevant Financial Relationships
It is the policy of AcademicCME that all faculty, instructors, and planners disclose relevant financial relationships relating to the topics of this educational activity. Any relevant financial relationships are mitigated via a content review by planning committee members and faculty with no relevant financial relationships.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:
|Faculty||Relationship Identified With:|
|Ann D. Bass, MD||Consultant/Advisor: Alexion Pharmaceuticals, Inc.; Biogen; Bristol-Myers Squibb Company; EMD Serono Inc.; Genentech, Inc.; Horizon Therapeutics plc; Novartis AG; Roche; Sanofi Genzyme and TG Therapeutics, Inc.
Research/Grant Support: Bristol-Myers Squibb Company; EMD Serono Inc.; Genentech, Inc.; Novartis AG; Roche; Sanofi Genzyme and TG Therapeutics, Inc.
Speaker’s Bureau: Alexion Pharmaceuticals, Inc.; Biogen; Bristol-Myers Squibb Company; EMD Serono Inc.; Genentech, Inc.; Horizon Therapeutics PLC; Novartis AG; Roche; Sanofi Genzyme and TG Therapeutics, Inc.
Planners and Peer Reviewers
Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; Nicole McMenamin and Chelsey Benedek hereby state that they or their spouse/life partner do not have any relevant financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council forPharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statements
AcademicCME designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits TM.
Clinicians should only claim credit commensurate with the extent of their participation.
This activity has been supported by an independent educational grant from Bristol-Myers Squibb Company.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Bristol-Myers Squibb Company do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
In order to claim credit, participants must complete the following:
- Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
- Complete the Pre-Activity Questions
- Read or Review the activity content.
- Complete the Post-Activity Test Questions and Evaluation.
- Learners who receive a grade of 60% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
- CPE credit will be posted to the learner’s CPE Monitor profile within 60 days of completion.
- CME and CNE credit will be issued appropriate certificate of completion.
- Others may request a “certificate of completion”.
- Learners should claim only the credit commensurate with the extent of their participation in the activity.
CE Inquiries/Special Needs
For all CE inquiries or special needs, please contact [email protected].